Nintedanib Esylate
Brand name: Ofev
Rank #24 of 500 drugs by total cost
$703.7M
Total Cost
53,928
Total Claims
$703.7M
Total Cost
1,757
Prescribers
$13K
Cost per Claim
2,118
Beneficiaries
54,796
30-Day Fills
$401K
Avg Cost/Provider
31
Avg Claims/Provider
About Nintedanib Esylate
Nintedanib Esylate (sold as Ofev) was prescribed 53,928 times by 1,757 Medicare Part D providers in 2023, costing the program $703.7M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology